Abiopharma

🔍 Catalyst4, Inc. (Executive)

Company: MapLight Therapeutics, Inc. (MLPT)

Report Date: 2026-07-28

Detailed Transactions and Holdings:

• Acquired 141,088 shares of Voting Common Stock at $10.7416 per share (Direct)
  Date: 2026-07-28 | Code: P | equity_swap_involved: 0 | shares_owned_after: 19,838,552.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 65,137 shares of Voting Common Stock at $11.6891 per share (Direct)
  Date: 2026-07-28 | Code: P | equity_swap_involved: 0 | shares_owned_after: 19,903,689.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Acquired 3,000 shares of Voting Common Stock at $12.63 per share (Direct)
  Date: 2026-07-29 | Code: P | equity_swap_involved: 0 | shares_owned_after: 19,906,689.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,000,000 shares of Voting Common Stock at $13.0 per share (Direct)
  Date: 2026-07-30 | Code: P | equity_swap_involved: 0 | shares_owned_after: 20,906,689.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.295 to $11.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
• F2: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
• F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.31 to $12.00, inclusive.